Site Editor

Thomas Flaig, MD

Advertisement

Advertisement

News

Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: The Debate Continues

Medical Literature

Newly Developed and Validated Prognostic Signature for Patients With Bladder Cancer

News

Can a Centralized, Multidisciplinary Program Improve Outcomes in Muscle-Invasive Bladder Cancer?

News

Successful Treatment of Rare Case of Urothelial Carcinoma of the Fossa Navicularis

News

Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: The Debate Continues

News

Independent Risk Factors of Bladder Cancer: Perspective From an Iranian Province

Medical Literature

Effect of Smoking-Related Lung Disease on Bladder Urothelial Carcinoma Survival

Thomas Powles, MD, PhD, on Enfortumab Vedotin-ejfv: New Standard of Care for Aggressive Urothelial Carcinoma?

Sumanta K. Pal, MD: Does Adding Berzosertib to Chemotherapy Improve Outcomes in Urothelial Carcinoma?

View More

Advertisement

JNCCN Spotlights

Enfortumab Vedotin-ejfv

Sacituzumab Govitecan-hziy

View More

More

News

Vaccine Plus Pembrolizumab Under Study in Non–Muscle-Invasive Bladder Cancer

Can Sugary Drinks Increase Bladder Cancer Risk?

Predicting Pathologic Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

Radical Cystectomy: Comparing Outcomes by Stage and Type of Bladder Cancer

Non–Muscle-Invasive Disease: BCG With or Without Novel Vaccine Tested in Phase II Trial

AUA 2021: Antibody Levels as Predictors of Response to Immunotherapy in Bladder Cancer

SITC 2021: Preclinical Study of Microbial Immunotherapy in Bladder Cancer

Can Smoking-Related DNA Methylation Markers Help to Predict Urothelial Cancer Risk?

View More

Advertisement

Published

Medical Literature

Update on Managing Non–Muscle-Invasive Bladder Cancer

Targeting Bladder Carcinoma in Situ With Novel Gene Therapy

Intravesical Nadofaragene Firadenovec in Non–Muscle Invasive Bladder Cancer

Impact of Preoperative Positive Voided Urine Cytology on Prognosis in Urothelial Cancer

View More

Ongoing

CE Activities

Metastatic Urothelial Carcinoma: 2020 Multidisciplinary Molecular Tumor Board

What's New for GU: Incorporating Novel Evidence Into Treatment for Genitourinary Malignancies

IO Therapies in the Advanced Bladder Cancer Clinic: Aligning Your Team for Success

Highlights from ASCO-GU: Advanced Urothelial Carcinoma

View More

Available

Clinical Trials

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

Tissue and Body Fluid Analysis from Patients with Bladder Cancer and Other Urothelial Cancers of the Urinary Tract

View More

Resources

For Your Patients

Bladder Cancer Advocacy Network

American Cancer Society

American Bladder Cancer Society

JNCCN: How To Manage Cancer Care During COVID-19 Pandemic

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2022 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.